Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan To  Create Special Zone To Speed Up Medical Technology Innovation

This article was originally published in PharmAsia News

Executive Summary

Four Japanese Ministries will cooperate to create a special zone for innovative technology, aiming to speed up the development and approval process for advanced technologies in regenerative medicine, biopharmaceutical products and medical devices. The Ministry of Health, Labor and Welfare; the Ministry of Education, Culture, Sports, Science and Technology; the Ministry of Economy, Trade and Industry; and the Ministry of State for Financial Services and Administrative Reform have all agreed to a proposal by Diet members

You may also be interested in...



Japan’s MHLW Steps Up Efforts To Reduce Drug Approval Lag Time

TOKYO - On the back of rising pressures, Japan's Ministry of Health, Labor and Welfare is stepping up efforts to shorten new drug approval periods that now are woefully behind other countries - yet finds the undertaking a tall task that may take longer than officials envisioned

ANDA Submissions Drop To Start FY2021

First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.

QUOTED. 22 January 2021. Neil Moat.

The Centers for Medicare and Medicaid Services has agreed to provide national Medicare coverage for mitral valve transcatheter edge-to-edge repair under a new coverage with evidence development policy. See what Neil Moat, chief medical officer for Abbott’s structural heart business, said about it here.

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel